ArticleScientific reports2025
The role of glucocorticoids in hepatocellular carcinoma through integrated bioinformatics analysis and experimental validation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The most widespread primary liver cancer around the world is hepatocellular carcinoma (HCC), and its rising incidence and mortality rates are major challenges for public health. This study investigates the role of glucocorticoids in HCC, focusing on their associated phenotypic genes and their impact on patient prognosis. Utilizing comprehensive bioinformatics approaches, a total of 751 differentially expressed genes were identified, with 470 showing increased expression and 281 showing decreased expression in tumor samples. Gene set enrichment analysis (GSEA) indicated that tumor samples showed significant enrichment in spliceosome, ribosome, and DNA replication pathways, while control samples were enriched in complement and coagulation cascades and drug metabolism pathways. Furthermore, based on glucocorticoid-related genes, consensus clustering categorized HCC samples into two subtypes, with subtype 2 exhibiting poorer prognosis. Immune infiltration analysis indicated significant differences in various immune cell types between the two subtypes, suggesting potential immune evasion mechanisms. Drug sensitivity analysis from the Genomics of Drug Sensitivity in Cancer (GDSC) database revealed that subtype 2 patients may be more responsive to certain drugs, such as Bortezomib and Dactinomycin. Furthermore, based on the established prognostic model, a total of four genes (KIF2C, CYP2C9, PON1, SPP1) were identified. These genes are both glucocorticoid-related receptors and closely associated with the development of hepatocellular carcinoma, and they have reliable diagnostic and prognostic value. DGIdb drug prediction shows that a variety of drugs and compounds can target these four genes. Finally, immunohistochemistry revealed that in contrast to normal liver tissues, KIF2C and SPP1 were highly expressed in tumor tissues, while CYP2C9 and PON1 were expressed at lower levels in tumor tissues. This study highlights the importance of glucocorticoid-related genes in the development and prognosis of HCC, providing insights for future experimental validation and clinical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.